• Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers, including patients, clinicians, hospitals, independent delivery networks (IDNs), health plans, employers, consumers, and accountable care organizations (ACOs). It is also engaged in two business operations, Diagnostic Information Services, which develops and delivers diagnostic information services that provide insights to a range of customers, and the Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology business, which offers solutions for healthcare providers. The Company’s services are primarily provided under the Quest Diagnostics brand and also provide services under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

  • Revenue in USD (TTM)9.60bn
  • Net income in USD789.00m
  • Incorporated1996
  • Employees40.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
Haystack Oncology IncAnnounced27 Apr 202327 Apr 2023Announced-8.13%450.00m
Newyork-Presbyterian Hospital-Laboratory Services BusinessDeal completed14 Feb 202314 Feb 2023Deal completed-7.77%--
Northern Light LaboratoryDeal completed08 Dec 202208 Dec 2022Deal completed-9.46%--
LabCare PLUSAnnounced05 Oct 202205 Oct 2022Announced5.31%--
Data delayed at least 15 minutes, as of Jun 07 2023 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.